CD63 and colorectal carcinoma: The results of the analysis of the two groups of samples obtained from healthy donors (n = 20) and CRC patients with stage IIIb-IV of the disease (n = 20) are summarized in Figure 3B. Shown are the quantification results for Meprin A(+)ENVs captured by immunobeads SPMP-AB and labeled with anti-CD63 antibodies (FITC signal, left) or anti-CD9 antibodies labeled with PerCP (right).